Latest Breaking News On - Tamaraa favorito - Page 1 : comparemela.com

Completed collaborative and productive pre-submission meeting with FDA for arimoclomol NDA in August 2023; filing expected in Q4 2023 Net revenue of $8.5M for Q2 2023, which includes $5 million. -Today at 07:31 am- MarketScreener

United statesNichol ochsnerChristal mickleTamaraa favoritoThomas andersonJennifer arcureEuropean medicines agencyDrug administrationCorium incExchange commissionZevra therapeutics incCompany early access programGlobenewswire incUs drug enforcement agencyZevra therapeuticsCorporate highlights